Rate My Professor Richard Christopherson

Christopherson's research centers on cancer biology, with expertise in chemotherapy, haematological tumours, oncology and carcinogenesis, biochemistry and cell biology, enzymes, and haematology. His work emphasizes chronic lymphocytic leukemia (CLL), proteomic profiling of cancer cells, lipid rafts in leukemia, nucleotide biosynthesis inhibitors as anti-cancer drugs, and synergistic drug combinations such as venetoclax with PI3K or AKT inhibitors, Hsp90 inhibitors with fludarabine, and ClpP activators. He has published over 232 papers, accumulating more than 4,400 citations and an h-index of 9. Key publications include 'The Hsp90 inhibitor SNX-7081 is synergistic with fludarabine nucleoside via DNA damage and repair mechanisms in human p53-negative chronic lymphocytic leukemia' (2016), 'Profiling the Lipid Raft Proteome from Human MEC1 Chronic Lymphocytic Leukemia Cells' (2014), 'The ClpP activator ONC-212 (TR-31) inhibits BCL2 and B-cell receptor signaling in CLL' (2021), 'IBL-202 is synergistic with venetoclax in CLL under in vitro conditions that mimic the tumor microenvironment' (2020), and 'Inhibitors of de Novo Nucleotide Biosynthesis as Drugs' (2000). In 2017, he was awarded the Member of the Order of Australia (AM) in the Queen's Birthday Honours for significant service to medicine through contributions to molecular bioscience. His research has influenced cancer diagnostics, biomarker discovery, and therapeutic strategies for hematologic malignancies.